IPP Bureau
Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients
By IPP Bureau - February 15, 2025
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
By IPP Bureau - February 15, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Bayer files for approval of finerenone in heart failure in Japan
By IPP Bureau - February 15, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
By IPP Bureau - February 14, 2025
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%
By IPP Bureau - February 14, 2025
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
By IPP Bureau - February 14, 2025
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Cupid receives Rs. 13.90 cr order for female condoms from Brazil, South Africa and Angola
By IPP Bureau - February 14, 2025
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy
By IPP Bureau - February 13, 2025
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Johnson & Johnson launches new intraocular lens TECNIS PureSee in India
By IPP Bureau - February 13, 2025
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
FDA approves Pfizer’s ADCETRIS combination regimen for the treatment of Relapsed/Refractory DLBCL
By IPP Bureau - February 13, 2025
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Utthunga partners with VindAir to advance smart solutions for pharma industry
By IPP Bureau - February 13, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains to replace Jonathan Hunt as CEO of Syngene
By IPP Bureau - February 11, 2025
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Lupin receives approval from USFDA for Ipratropium Bromide Nasal Solution
By IPP Bureau - February 11, 2025
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Jagsonpal Pharmaceuticals appoints Sachin Jain as CFO
By IPP Bureau - February 10, 2025
He has over 23 years of experience across sectors
.jpg "Briefs: Caplin Point Laboratories, Hikal and Cipla")
Briefs: Caplin Point Laboratories, Hikal and Cipla
By IPP Bureau - February 10, 2025
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
